ConductScience.org, home

Paper40041202

Clinical value of the MGMT promoter methylation score in IDHmt low-grade glioma for predicting benefit from temozolomide treatment.

Darlix A and 12 others. Neurooncol Adv, 2025. Cited by 4 papers, by iCite.

Cite this record

ConductScience Library. Clinical value of the MGMT promoter methylation score in IDHmt low-grade glioma for predicting benefit from temozolomide treatment. Papers, record 40041202. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/40041202

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Clinical value of the MGMT promoter methylation score in IDHmt low-grade glioma for predicting benefit from temozolomide treatment.
PubMed
Journal
Neurooncol Adv
PubMed
Year
2025
PubMed
Publication types
Journal Article
PubMed
Citations, by iCite
4
iCite
Relative citation ratio, by iCite
0.59, provisional
iCite
Revised in PubMed
2025-03-06
PubMed

Authors13

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Darlix AAmélie
2Bady PPierrehttps://orcid.org/0000-0003-1398-4689
3Deverdun JJérémy
4Lefort KKarine
5Rigau VValériehttps://orcid.org/0000-0002-8017-5489
6Le Bars EEmmanuelle
7Meriadec JJustinehttps://orcid.org/0000-0002-3927-9868
8Carrière MMathilde
9Coget AArthur
10Santarius TThomas
11Matys TTomaszhttps://orcid.org/0000-0003-2285-5715
12Duffau HHugueshttps://orcid.org/0000-0002-6558-2342
13Hegi MEMonika Ehttps://orcid.org/0000-0003-0855-6495

Source PubMed

Download CSV of authors

Topics0

NLM's MeSH indexing of the paper, its major topics first.

None in this release.

References36

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
119665931Cognitive and radiological effects of radiotherapy in patients with low-grade glioma: long-term follow-up.Lancet Neurol2009https://conductscience.org/library/papers/19665931PubMed
229368212The DNA methylome of DDR genes and benefit from RT or TMZ in IDH mutant low-grade glioma treated in EORTC 22033.Acta Neuropathol2018https://conductscience.org/library/papers/29368212PubMed
337272516Vorasidenib in IDH1- or IDH2-Mutant Low-Grade Glioma.N Engl J Med2023https://conductscience.org/library/papers/37272516PubMed
430258934InfiniumPurify: An R package for estimating and accounting for tumor purity in cancer methylation research.Genes Dis2018https://conductscience.org/library/papers/30258934PubMed
530753579Recent developments and future directions in adult lower-grade gliomas: Society for Neuro-Oncology (SNO) and European Association of Neuro-Oncology (EANO) consensus.Neuro Oncol2019https://conductscience.org/library/papers/30753579PubMed
631386080Chemotherapy and diffuse low-grade gliomas: a survey within the European Low-Grade Glioma Network.Neurooncol Pract2019https://conductscience.org/library/papers/31386080PubMed
727157931The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary.Acta Neuropathol2016https://conductscience.org/library/papers/27157931PubMed
827542245Validation of the high-performance of pyrosequencing for clinical MGMT testing on a cohort of glioblastoma patients from a prospective dedicated multicentric trial.Oncotarget2016https://conductscience.org/library/papers/27542245PubMed
937585632Headway against Brain Tumors with Molecular Targeting of IDH-Mutant Gliomas.N Engl J Med2023https://conductscience.org/library/papers/37585632PubMed
1032166314MGMT promoter methylation level in newly diagnosed low-grade glioma is a predictor of hypermutation at recurrence.Neuro Oncol2020https://conductscience.org/library/papers/32166314PubMed
1122810491
MGMT methylation analysis of glioblastoma on the Infinium methylation BeadChip identifies two distinct CpG regions associated with gene silencing and outcome, yielding a prediction model for comparisons across datasets, tumor grades, and CIMP-status.
Acta Neuropathol2012https://conductscience.org/library/papers/22810491PubMed
1227050206Radiation plus Procarbazine, CCNU, and Vincristine in Low-Grade Glioma.N Engl J Med2016https://conductscience.org/library/papers/27050206PubMed
1316632515Adjusting batch effects in microarray expression data using empirical Bayes methods.Biostatistics2007https://conductscience.org/library/papers/16632515PubMed
1428640707Response Assessment in Neuro-Oncology Clinical Trials.J Clin Oncol2017https://conductscience.org/library/papers/28640707PubMed
1516168780Long-term efficacy of early versus delayed radiotherapy for low-grade astrocytoma and oligodendroglioma in adults: the EORTC 22845 randomised trial.Lancet2005https://conductscience.org/library/papers/16168780PubMed
1611146149Sample-size calculations for the Cox proportional hazards regression model with nonbinary covariates.Control Clin Trials2000https://conductscience.org/library/papers/11146149PubMed
1727686946Temozolomide chemotherapy versus radiotherapy in high-risk low-grade glioma (EORTC 22033-26033): a randomised, open-label, phase 3 intergroup study.Lancet Oncol2016https://conductscience.org/library/papers/27686946PubMed
1825008768Integrated DNA methylation and copy-number profiling identify three clinically and biologically relevant groups of anaplastic glioma.Acta Neuropathol2014https://conductscience.org/library/papers/25008768PubMed
1915758010MGMT gene silencing and benefit from temozolomide in glioblastoma.N Engl J Med2005https://conductscience.org/library/papers/15758010PubMed
2039277807MGMT promoter methylation and survival following chemotherapy for WHO grade 4 IDH-mutant astrocytoma.Neuro Oncol2024https://conductscience.org/library/papers/39277807PubMed

See all 36 referencesDownload CSV of references

Cited by3

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 4 citations.

PMIDTitleJournalYearIn PapersSource
42313202MGMT promoter methylation across glioma subtypes: biological relevance, treatment response, and survival outcomes.Mol Biol Rep2026https://conductscience.org/library/papers/42313202PubMed
41677997Targeting metabolic mechanisms to overcome temozolomide resistance in glioblastoma.Discov Oncol2026https://conductscience.org/library/papers/41677997PubMed
41460180Distinct molecular profiles characterize the spontaneous growth rate of IDHmt low-grade astrocytomas and oligodendrogliomas.Neuro Oncol2026https://conductscience.org/library/papers/41460180PubMed

Download CSV of cited by

Genes2

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn GenesSource
IDH13417PubTator's text mininghttps://conductscience.org/library/genes/3417NCBI Gene
MGMT4255PubTator's text mininghttps://conductscience.org/library/genes/4255NCBI Gene

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/40041202

GET https://conductscience.org/api/papers/v1/40041202/references?page=2